PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11483875-5	2001	After bezafibrate therapy, HDLc increased from 0.79-1.0 mM (p = 0.0008) at the expense of both HDL2 and HDL3 subfractions, apolipoprotein A-I increased from 1.04-1.19 g/l (p = 0.0012), and fibrinogen decreased from 4.45-3.39 g/l (p = 0.0007).	Bezafibrate	6-17	junctophilin 3	Homo sapiens	95-99	
16891292-0	2006	Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.	Bezafibrate	11-22	junctophilin 3	Homo sapiens	26-30	
3884023-1	1985	In our study, bezafibrate in short-acting formula and long-acting formula, administered to hyperlipidaemic patients, resulted in a significant lowering of atherogenic lipids and lipoproteins (chol.-T, LDL and VLDL-chol., apolipoprotein B and VDLD-TR), and a marked increase in the levels of HDL, HDL2, HDL3-chol.	Bezafibrate	14-25	junctophilin 3	Homo sapiens	296-300	
8060379-6	1994	Bezafibrate did not affect the plasma level of HDL2-TC but reduced the HDL2-TG concentration significantly (P < 0.001).	Bezafibrate	0-11	junctophilin 3	Homo sapiens	71-75	
1397477-5	1992	The marked BZF-induced Tg reduction was associated with a proportional decrease in Apo B, while an increase in total HDL-, HDL2 and HDL3-CHOL, together with a significant increase in Apo AI, was observed.	Bezafibrate	11-14	junctophilin 3	Homo sapiens	123-127	
7236016-0	1980	Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.	Bezafibrate	10-21	junctophilin 3	Homo sapiens	67-71	
7236016-1	1980	The effect of a six-month treatment with bezafibrate on HDL2 and HDL3, measured as cholesterol and apolipoprotein A-I, was studied in 10 hypertriglyceridemic patients.	Bezafibrate	41-52	junctophilin 3	Homo sapiens	56-60